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Human Induced Pluripotent Stem Cells Improve Stroke Outcome  
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Human induced pluripotent stem cells (hiPSCs) are a most appealing source for cell replacement therapy in 
acute brain lesions. We evaluated the potential of hiPSC therapy in stroke by transplanting hiPSC-derived neu-
ral progenitor cells (NPCs) into the postischemic striatum. Grafts received host tyrosine hydroxylase- positive 
afferents and contained developing interneurons and homotopic GABAergic medium spiny neurons that, with 
time, sent axons to the host substantia nigra. Grafting reversed stroke-induced somatosensory and motor defi-
cits. Grafting also protected the host substantia nigra from the atrophy that follows disruption of reciprocal 
striatonigral connections. Graft innervation by tyrosine hydoxylase fibers, substantia nigra protection, and 
somatosensory functional recovery were early events, temporally dissociated from the slow maturation of 
GABAergic neurons in the grafts and innervation of substantia nigra. This suggests that grafted hiPSC-NPCs 
initially exert trophic effects on host brain structures, which precede integration and potential pathway recon-
struction. We believe that transplantation of NPCs derived from hiPSCs can provide useful interventions 
to limit the functional consequences of stroke through both neuroprotective effects and reconstruction of 
impaired pathways.
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Neurovascular lesions
human origin (5,7,27,35,47,53). Encouraging experimen-
tal data have fostered Phase I–II trials, so far published 
with BMSCs and neural cell lines (3,24).
Induced pluripotent SCs (iPSCs) (45) have added a 
unique source to the panel of available resources for SC 
therapy. IPSCs possess the cardinal features of ESCs, plu-
ripotency and unlimited self-renewal, which are definitive 
assets for the large-scale and standardized production of 
therapeutic products. In addition, hiPSCs have the poten-
tial to overcome immune rejection with human leukocyte 
antigen (HLA)-specific cells (23,34). On the iPSCs “dark 
side,” reprogramming can leave epigenetic and genetic 
IntRODuCtIOn
Despite decades of academic and industrial research, 
cerebrovascular diseases continue to thwart the attempts 
of developing neuroprotective treatments and remain a 
leading cause of death and long-term disability worldwide 
(49). The proof of principle of stem cell (SC) therapy in 
stroke has been provided at experimental level with a 
wide array of cell sources that, not exhaustively, include 
neural progenitors from fetal and adult neural tissues, 
mesenchymal SCs from bone marrow (BMSCs) or umbil-
ical cord blood, peripheral blood cells, immortalized cell 
lines, and embryonic SCs (ESCs) of rodent, primate, and 
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modifications (17,21,28,48) with still unknown func-
tional repercussions. As a result, the fate and effects of 
iPSC-derived neural progeny must be thoroughly inves-
tigated in preclinical models before therapies based on 
hiPSCs are proposed to clinicians (10).
In contrast with the unprecedented therapeutic options 
offered by iPSCs, illustrations of therapeutic transplanta-
tion applications are still scarce. Thus far, two reports have 
described iPSC transplantation in stroke models, firstly, 
confirming their ability to form teratoma after intracere-
bral transplantation (20) and, secondly, showing a reduc-
tion of stroke-induced motor dysfunction after subdural 
transplantation with fibrin glue (9). Both reports were 
performed with undifferentiated mouse iPSCs, leaving 
the potential of human neural derivatives unexplored.
In this study, hiPSC-derived neural progenitor cells 
(NPCs) were used to define their ability to reverse stroke-
induced functional and structural impairments after intra-
cerebral transplantation. Our results show that hiPSC-NPCs 
not only rescue sensorimotor and motor functions but 
protect remote areas connected with the lesioned site 
from atrophy. Mismatches in the kinetics of functional 
and structural events suggest the existence of sequential 
mechanisms, independent, then dependent, on homotopic 
cell replacement and reconstruction of lost pathways.
MateRIalS anD MetHODS
Validation of hiPSC Lines and Neural Induction
The I-Stem-Strasbourg (I-S)hiPSC lines were derived 
from MRC5 and IMR90 human fetal lung fibroblasts 
(ATCC, Manassas VA, USA) transduced with the pSin-
EF2-octamer-binding transcription factor 4 (Oct4)-Pur, 
pSin-EF2-sex-determining region Y Box 2 (Sox2)-Pur, 
pSin-EF2-Nanog-Pur, and pSin-EF2-Lin28-Pur13 plas-
mids from Addgene (Cambridge, MA, USA) according 
to Yu et al. (52). Viruses were produced by Vectalys 
(Labège, France; MOI between 7 and 23). The culture 
medium (Dulbecco’s modified Eagle medium containing 
10% fetal bovine serum) was progressively modified over 
1 week to serum-free hESC medium containing 20 ng/
ml basic fibroblast growth factor (bFGF; R&D Systems, 
Minneapolis, MN, USA). Transduced fibroblasts were 
seeded onto mouse embryonic feeder cells and grown in 
hESC medium. Colonies with ESC morphology appeared 
after 3–6 weeks and were clonally expanded for 5 weeks 
with mechanical passage every 5–7 days. Seven colonies 
from IMR90 and five from MRC5 cultures were selected 
on a morphological basis and validated for the expres-
sion of hESC self-renewal genes and surface markers 
and for pluripotency through embryoid bodies and tera-
toma formation before commitment into the neural lin-
eage. Data were compared to hESC lines that included 
the SA001 (XY; Cellartis AB, Gothenburg, Sweden), H9 
(XX; WiCell, Madison, WI, USA), and CCTL14 (XX; 
Masaryk University, Brno, Czech Republic) lines.
Quantitative PCR Analysis
Real-time quantitative (q) PCR (Primer list in Table 1) 
was performed with the RNeasy microkit (Qiagen, France) 
and Superscript III reverse transcriptase (Invitrogen, France) 
on 0.5 µg cDNA. Normalization was achieved against 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
RNA using the DDCt method for quantification (ABI-
Prism Software, Applied Biosystems).
Flow Cytometry Analysis
Flow cytometry (FACSCalibur Flow Cytometer, BD 
Biosciences) analysis of the ESC-specific cell surface 
markers stage-specific embryonic antigen-1 (SSEA-1) 
[mouse IgM coupled to allophycocyanin (APC)], SSEA-4 
(mouse IgG3 coupled to Alexa-Fluor 488), and TRA-1-81 
[mouse IgM coupled to phycoerythrin (PE)] was performed 
table 1. List of Primers Used for qRT-PCR
Gene Forward Reverse Size
OCT3/4 CTTGCTGCAGAAGTGGGTGGAGGAA CTGCAGTGTGGGTTTCGGGCA 168
NANOG CAAAGGCAAACAACCCACTT TCTGCTGGAGGCTGAGGTAT 158
SOX2 ACAGCAAATGACAGCTGCAAA TCGGCATCGCGGTTTTT 67
KLF4 TATGACCCACACTGCCAGAA TGGGAACTTGACCATGATTG 110
LIN28 GGCAGTGGAGTTCACCTTT GCTTCTGCATGCTCTTTCCT 123
DNMT CCAATCCTGGAGGCTATCCG ACTGGGGTGTCAGAGCCAT 152
CRIPTO AAGATGGCCCGCTTCTCTTAC AGATGGACGAGCAAATTCCTG 108
CK18 TGAGACGTACAGTCCAGTCCT GCTCCATCTGTAGGGCGTAG 114
KDR AGCGATGGCCTCTTCTGTAA ACACGACTCCATGTTGGTCA 172
SOX17 CCTGGGTTTTTGTTGTTGCT GCTGTTTTGGGACACATTCA 206
AFP ACTGCAATTGAGAAACCCACTGGAGATG CGATGCTGGAGTGGGCTTTTTGTGT 192
GAPDH ATGGGGAAGGTGAAGGTCGGAG TCGCCCCACTTGATTTTGGAGG 266
DNMT, DNA methyltransferase; CK18, cytokeratin 18; KDR, kinase insert domain protein receptor; AFP, a-fetoprotein; GAPDH, glyceraldehyde 
3-phosphate dehydrogenase.
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on the selected clones and on SA001 with appropriate iso-
type controls (all antibodies from BD Biosciences).
Embryoid Bodies Formation
Embryoid bodies (EBs) were formed after collagenase 
dissociation (1 mg/ml, Invitrogen) and seeding on ultra-
low attachment plates (Nunc, Dutscher) for 3–6 weeks 
without bFGF. EBs were analyzed after 4 and 14 days by 
qPCR for markers of the three germ layers.
Karyotype Analysis
I-ShiPSCs were harvested for metaphase chromo-
somes at 70% confluence. G-banding chromosome ana-
lysis was performed with the Wright/Giemsa (Merck) 
technique after colchicine (20 mg/ml, Eurobio) incuba-
tion, hyptonic shock (KCl 0.057 M), and fixation with 
Carnoy’s solution (3:1 methanol/acetic acid). Analysis 
was performed with the Ikaros software (MetaSystems, 
Altussheim). Multicolor fluorescent in situ hybridiza-
tion (mFISH) were performed at passages 18 (both lines) 
and at p56 (I-I90) or p59 (I-M5) with the cocktail paint-
ing Probe Cy5 B-tect detection kit and Isis software 
(MetaSystems, Altussheim).
Teratoma Formation
Pluripotency was further investigated with the tera-
toma test performed in nonobese diabetic/severe com-
bined immunodeficient mice (NOD/SCID; Charles River, 
France) after subcutaneous injection of 2 ´  106 cells, with 
anatomo-pathological analysis 2 months postinjection.
Neural Induction
Early neural precursors (ENPs) were produced in low-
attachment cultures in the presence of Noggin (R&D 
Systems), the transforming growth factor-b pathway 
inhibitor SB431542 (Tocris Biosci.), bFGF (10 µg/ml, 
Preprotech), and human brain-derived growth factor 
(hBDNF; 20 µg/ml, R&D Systems) (8). NPCs were pro-
duced from ENPs in the presence of 20 ng/ml hBDNF 
for 7 days. Expression levels of pluripotency and neural 
cell markers were quantified by qPCR and flow cytom-
etry, respectively. Fluorescence-activated cell sorting 
(FACS) antibodies included anti-Nanog, TRA-1-60 and 
SSEA4 (eBioscience), CD29, CD15 (SSEA1), CD56 
(neural cell adhesion molecule, NCAM), and bIII-tubulin 
(all from BD Pharmingen), along with unconjugated 
mouse primary antibodies against nestin and neurofila-
ment 70 kDa (NF70) (Abcam), secondary rat anti-mouse 
IgG conjugated with fluorescein isothiocyanate (FITC; 
eBioscience), and secondary donkey anti-rabbit IgG con-
jugated with APC (Jackson ImmunoResearch Labs).
Voltage clamp was used to record potassium outward 
current in the whole-cell configuration (20–25°C) filtered 
at 3.3 kHz, using the HEKA data acquisition/analysis 
system. Pipettes (5–7 MΩ) were pulled from borosilicate 
glass with P97-sutter and filled with (mM): KCl 155, 
MgCl2 2, CaCl2 1, HEPES 10, and EGTA 10 (pH 7.3). 
Cells were maintained in (mM): NaCl 150, CaCl2 3, KCl 
2.5, MgCl2 1, HEPES 10 (pH 7.6). Steps of +10 mV from 
the holding voltage Vh-90 mV were applied during 50 ms 
to record A-type calcium current (IA), 500 ms to record 
delayed rectifying current (IDR), and 50 ms to record 
voltage-gated sodium current (INa).
Experimental Surgery
All animal experimentation was performed in com-
pliance with European ethical guidelines (86/609/EEC). 
Adult male (280 g) Sprague–Dawley rats (Charles 
River; n = 187) were anesthetized (1–2% isoflurane/30% 
oxygen/75% nitrous oxide) before receiving a 90-min 
middle cerebral artery occlusion MCAO (30) with a hepa-
rinized 4.0 nylon monofilament (Doccol Corporation; 
(40) SPPK5; MyDesign MCAO suture PK5; coating 
length 2–3 mm, tip diameter 0.35 ± 0.02 mm). Rectal tem-
perature was maintained between 36.7°C and 37.5°C with 
a homeothermic blanket (Harvard Apparatus). Three ani-
mals died during MCAO surgery, either during anesthesia 
(n = 1) or at reperfusion (n = 2). One week after MCAO, 
animals were randomly distributed into four groups: 
Control (MCAO nongrafted; n = 35), I-I90-NPC (n = 29), 
I-M5-NPC (n = 29), and SA001-NPC (n = 15). A group of 
nonlesioned/nongrafted animals (n = 12) was also used for 
quantification of substantia nigra (SN) volumes. Grafted 
animals received a stereotaxic injection of 1 µl of culture 
medium (Control) alone or containing 100,000 NPCs from 
I-I90, I-M5, or SA001 (coordinates from bregma A-P: 0.5 
mm; Lat: 2 mm; D-V: 5.5 mm) with a needle inclination of 
15° to reach the lesion cavity in the lateral quadrant of the 
striatum. Three additional animals died during this proce-
dure (two during anesthesia, one from bleeding at removal 
of the needle), resulting in a final distribution of Control 
(n = 34), I-I90-NPC (n = 28), I-M5-NPC (n = 29), SA001-
NPC (n = 14). Animals were immunosuppressed with a 
daily injection of 10 mg kg-1 cyclosporine A (Sandimmun, 
Novartis) starting the day before transplantation for 
2 months. Body weight was followed daily.
Behavioral Analysis
All behavioral tests were conducted by investiga-
tors blinded to the experimental conditions. To avoid 
habituation of animals to repeated behavioral investiga-
tion (18), I-I90-NPC-grafted animals were used for the 
adhesive removal test and I-IM5-NPC-grafted animals 
for the staircase test. Animals grafted with I-I90-, I-M5- 
and SA001-NPCs were used for the apomorphin-induced 
rotation test. For the adhesive removal test (I-I90: n = 28; 
Nongrafted: n = 19 at the start of experiment), a sticky 
colored paper dot (12 mm diameter) was placed on the 
2590 POLENTES ET AL.
rat left palm and fingers, and the time to remove the dot 
was measured. Rats were pretrained for 4 days before 
MCAO and were tested three times a week. The stair-
case test was performed with sucrose pellets (Campden 
Instruments Ltd.; three pellets on each side). Animals 
(I-M5: n = 29; Nongrafted: n = 15 at the start of the experi-
ment) were food-deprived to 85% of their normal weight 
and trained for 3 weeks (two trials per day, 5 days a week) 
before MCAO and three times a week after transplanta-
tion. Scores indicate the number of pellets grasped by the 
paw contralateral to the lesion. The apomorphin-induced 
rotation test (motor dysfunction, pharmacological) was 
performed on grafted (I-I90: n = 28; I-M5: n = 29; SA001: 
n = 14 at the start of the experiment) and on nongrafted 
(n = 34) animals. Turns were counted during 30 min fol-
lowing intraperitoneal injection of 1 mg/kg apomorphin–
HCl (Sigma). Deficits were quantified using the formula 
modified from Arvidsson et al (2): Score = IspiCyl + (2 ´  
IpsiItself) - ContrCyl - (2 ´  ContrItself), where IpsiCyl: 
rotation ipsilateral to the lesion around central cylinder, 
IpsiItself: rotation ipsilateral on itself, ContrCyl: rotation 
contralateral to the lesion around the central cylinder, 
ContrItself: rotation contralateral on itself. Neurological 
severity scores (NSS) were performed on all groups up to 
4 months postgrafting (39). Function was graded on a 0 
(normal) to 10 (severely impaired) scale.
Tissue Processing
Rats were anesthetized with 150 mg/kg sodium pen-
tobarbital before intracardiac perfusion with 4% para-
formaldehyde phosphate-buffered to pH 7.4. Brains were 
postfixed overnight in the same fixative solution and cryo-
protected with 30% sucrose for 48 h. Thirty-micrometer-
thick cryostat sections were serially collected with a Leica 
CM cryostat. Immunohistochemistry was performed with 
rabbit polyclonal antibodies to human nestin (Chemicon, 
AB5922), glial fibrillary acidic protein (GFAP; Sigma, 
G9269), dopamine- and cAMP-regulated neuronal phos-
phoprotein (DARPP-32; Santa Cruz Biotech., sc-21601), 
paired box protein 6 (Pax6; Covance, PRB-278P), unspe-
cific tyrosine hydroxylase (TH; Jacques Boy, 208020234), 
Ki67 (Abcam, ab833), and neuron-specific class III beta-
tubulin (TUJ1; Covance, MMS-435P) and with mouse 
IgG antibodies to human nuclei (HNA; Chemicon, 
MAB1281), human mitochondria (MTCO2, Abcam, 
3298), Oct4 (Santa Cruz Biotech., SC-5279), human 
NCAM (SantaCruz Biotech., sc-106), and microtubule-
associated protein 2 (MAP2; Sigma, M1406). Secondary 
antibodies were Alexa488- or Alexa555-labeled (A11001 
and A21428, respectively, Invitrogen). IB4 labeling was 
performed with isolectin Griffonia simplicifolia (GS)-
IB4 biotin conjugate (Invitrogen, I2141) and revealed 
with Alexa647 (Jackson Labs., 016-600-084). DAPI 
(4¢,6-diamidino-2-phenylindole) was used to visualize 
the nuclei. Colorimetric immunohistochemistry was per-
formed using a Discovery XT (Ventana) staining auto-
mate. Controls were performed with the corresponding 
isotype when available or with secondary antibodies only. 
Observations were made using a Zeiss Axioplan micro-
scope, and image analysis was performed with ImageJ 
(http://rsb.info.nih.gov/ij). Confocal microscopy was done 
on a Zeiss LSM Pascal Exciter microscope. Ki67-, 
DARPP-32- and TH-positive neuron counts were per-
formed with unbiased stereological evaluation on three 
(Ki67) or six (DARPP-32) consecutive 30-µm-thick sec-
tions at 120-µm interval. TH-positive neuron counts were 
performed from level –4.8 to –6.3 from bregma, indepen-
dently of the SN volume. Volumes were calculated using 
the FreeD software (1).
Magnetic Resonance Imaging (MRI)
MRI was performed using a 4.7-T Bruker spectrometer 
equipped with a custom made surface coil. A T2-weighted 
turbospin echo sequence rapid acquisition with relaxation 
enhancement [RARE; repetition time (TR) = 3,000 ms, 
effective echo time (TE) = 36.0 ms, turbo factor = 8, num-
ber of acquisitions (AC) = 8, field of view = 3.5 cm, 
matrix = 256 ´  256, slice thickness = 0.85 mm, acquisition 
time = 9¢36²] was used.
Statistical Analysis
Data are expressed as means ± standard deviation. Stat-
istical analyses were performed using the JMP software 
(SAS). A value of p < 0.05 was considered significant.
Data were analyzed using one-way or repeated-
 measures ANOVA and Student’s t test, with Bonferroni–
Dunn post hoc test.
ReSultS
Production of hiPSC and Transplants
The two I-ShiPSC lines, I-I90 (XX) (25) and I-M5 
(XY), were validated by comparison to the SA001 
(Cellartis AB) and H9 (WiCell) hESC lines (Figs. 1 and 2). 
I-ShiPSC presented all characteristics of pluripotent 
SCs, including morphology (Fig. 1A, B), expression of 
hESC-specific markers (Fig. 1C–E), methylation pattern 
on OCT4 and NANOG promoters (Fig. 1F), and karyo-
type stability (Fig. 1G, H). I-ShiPSCs were able to pro-
duce EBs (Fig. 2A, B) with hESC-like gene expression 
(Fig. 2C, D) and formed teratoma after implantation into 
the immunodeficient mouse (Fig. 2E–H). Early neural 
precursors (ENPs) were derived using the dual-small body 
size mothers against decapentaplegic (SMAD) inhibition 
protocol described for hESCs (Fig. 3). Rosette-like ENPs 
(Fig. 3A) contained Nanog (Fig. 3B), Pax6 (Fig. 3C), and 
no Oct4 (Fig. 3C). RT-PCR revealed elevated levels of 
Nanog mRNA in I-ShiPSC-ENPs (Table 2). I-M5-ENPs 
additionally exhibited elevated Sox2 mRNA contents 
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(Table 2). Nanog mRNA levels were no longer elevated 
in NPCs (Fig. 3H), which displayed levels of neuronal 
differentiation markers similar to hESC-NPCs (Fig. 3H). 
NPCs were uniformly labeled for Sox2 (Fig. 3D) and 
contained TUJ1-positive neurons (Fig. 3D) and a small 
proportion of GFAP astrocytes (Fig. 3E). Neuronal differ-
entiation was confirmed with electrophysiology (Fig. 3I) 
(see legend). The ability of I-ShiPSC-NPCs to maintain 
their neuronal commitment into a rat brain environment 
was assessed in vitro by seeding on primary cultures of 
embryonic rat cortex (Fig. 3F). Neuronal differentiation 
was observed within 2 days (Fig. 3G).
Figure 4 depicts the global scheme of the experiments.
hiPSC-NPCs Differentiate Into GABAergic Neurons 
After Transplantation Into the Postischemic Brain
As previously described in this paradigm (40), 90 min 
MCAO resulted in a lesion restricted to the lateral quad-
rant of the striatum (Fig. 5A) in 65% of the animals. The 
other animals had larger lesions, encompassing the corti-
cal and subcortical territories of the artery (Fig. 5B), and 
were not kept in the study. One month after transplan-
tation, grafts could be identified on T2-weighted MRI 
(Fig. 5C) and histology (Fig. 5D). Cells were packed 
at injection site, with some scattered into the proximal 
parenchyma (Fig. 5E), and were mainly nestin positive 
(Fig. 5F). Grafts also contained cells positive for Sox2 
(Fig. 5G) and Pax6 (Fig. 5H), but not for Oct4 (Fig. 5G), 
indicating sustained neural commitment in the postisch-
emic environment. Host-graft interactions were illustrated 
by human MAP2 processes entering the host tissue 
(Fig. 5I) and by patches of host-derived tyrosine hydoxy-
lase (TH)-positive axons (Fig. 5J) into the grafts. DARPP-
32-positive neurons with an immature morphology were 
distributed in patches over the whole graft, indicating 
Figure 1. Validation of I-ShiPSC lines. (A, B) I-ShiPSC colo-
nies displayed a hESC-like morphology (A: I-I90; B: SA001). 
(C) Quantitative PCR of self-renewal and pluripotency markers. 
Relative expression levels normalized to GAPDH. Mean ± SD 
of three independent experiments. I-ShiPSCs display no sig-
nificant differences to SA001. (D) Flow cytometry for hESCs-
 specific cell surface markers. Levels of the pluripotency markers 
SSEA4 and TRA-1-81 and the differentiation marker SSEA1 in 
I-ShiPSCs and hESCs are similar. (E) Immunohistochemistry 
and FACS plots for both I-ShiPSC lines illustrating the expres-
sion of hESC-specific markers. Scale bar: 80 µm. (F) DNA 
methylation status of OCT4 and NANOG promoter regions in 
hESCs, I-ShiPSC lines, and corresponding fibroblasts. Open 
and closed circles indicate unmethylated and methylated CpG 
dinucleotides, respectively. (G, H) Examples of karyotype per-
formed with G banding (G: I-M5) and mFISH (H: I-I90) show-
ing the absence of aneuploidy and a normal set of 46 XY (I-M5) 
or XX (I-I90) human chromosomes after 56 or 59 passages, 
respectively.
FaCInG COluMn
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that some NPC had initiated terminal  differentiation 
(Fig. 5M). Similar results were obtained with SA001-
NPCs (Fig. 5K, L)
After 4 months, the graft had spread into the lesion 
cavity, although enlargement of the lateral ventricle was 
still visible (Fig. 6A). Grafts formed a mixed tissue with 
host-derived blood vessels (Fig. 6B) and astrocytes 
(Fig. 6C). GABAergic striatal neurons formed clusters 
of fully differentiated hDARPP-32-positive neurons 
(Fig. 6D, E) and scattered calretinin-positive interneu-
rons (Fig. 6F) were observed. In addition to DARPP-32, 
a D1-receptor-linked protein, a subpopulation of grafted 
neurons had type 2 dopaminergic receptors (Fig. 6G). 
The number of DARPP-32 neurons was not significantly 
different among grafts from the three cell types: SA001: 
172.43 ± 7.65 cells/mm3; I-M5: 140.59 ± 10.74 cells/mm3; 
I-I90: 162 ± 13.04 cells/mm3 (one-way ANOVA: p = 0.84; 
F = 0.18; dll = 19).
Figure 2. Assessment of I-ShiPSCs pluripotency. (A) Embryoid bodies (EBs) formed with I-M5. (B) Expression of neuron-specific 
class III beta-tubulin (green) and Pax6 (red) in a discrete area of an I-I90-derived EBs (day 7) showing neural differentiation. Arrow 
points to a neural rosette. (C) Microfluidic card of human SCs pluripotency genes; example of I-M5- and SA001-EBs at 4 and 14 days. 
Levels of gene expression relative to GAPDH are indicated by color changes, from red (high expression levels, low ∆Ct) to green (low 
expression levels, high ∆Ct). EP2102: control embryonal carcinoma cell line used as a reference for hESC. (D) QPCR for markers of 
differentiation in EBs from I-ShiPSCs and SA001 (Ectoderm: cytokeratin 18 (CK18); Mesoderm: Gata4, KDR; Endoderm: Sox17). 
The SA001-EBs mRNA levels are set as 1. Mean ± SD of two independent experiments. GAPDH levels were stable among cell lines: 
mean GAPDH Ct in EBs = 29.12 ± 1.06. (E–H) Example of teratoma derived from I-I90 showing secretory epithelium (E), smooth 
muscle (F), pigmented epithelium (G), and neural tissue (H). Scale bar: 250 µm.
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Figure 3. I-ShiPSCs differentiation into ENPs and functional NPCs. (A) ENPs form typical neural rosettes still display detectable 
levels of Nanog (B), express Pax6 (C) and do not express Oct4 (C). (D) After 7 days of differentiation, NPCs characterize by homog-
enous Sox2 expression and the presence of TUJ1-positive young neurons. (E) NPCs generate a small proportion of GFAP-positive 
astrocytes (2.77 ± 0.02%). (F, G) Differentiation of NPCs into young (2 days; F) and mature (5 days; G) neurons after seeding on rat 
cortex primary culture. (H) FACS analysis showing a similarly low expression of hESC markers (Nanog, SSEA4, TRA-1-60) and 
high expression of neuronal differentiation markers (Nestin, NCAM, NF70, bIII-tubulin, integrin CD29) in NPCs from I-ShiPSCs 
and hESCs (CCTL14 line). (I) Representative electrophysiological traces of patch-clamp recording showing fast transient current (IA) 
and delayed rectifier current (IDR) in ENPs. Sodium channels (INa) indicative of full neuronal maturation appear in NPCs within 
5–7 days of differentiation.
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Sustained proliferation is a major side effect after 
grafting NPC into the lesioned striatum. Quantification 
of the mitotic activity with Ki67 immunoreactivity iden-
tified 2.34 ± 0.3% dividing cells in grafts at 4 months. 
However, the absence of colocalization with the human 
mitochondrial marker MTCO2 indicated that these cells 
were of host origin (Fig. 6H). No nonneural structures 
and no overgrowths were observed along the 4 months 
of the study.
hiPSC-NPCs Rescue Functional Impairments
Scoring of sensorimotor dysfunction (Fig. 7) with 
the tape removal test indicated a significant recovery 
of grafted animals from 2 weeks posttransplantation 
(Fig. 7A). Significance was maintained over the 4 months 
of the study, in spite of an important recovery in non-
grafted animals. As reported, MCAO animals typically 
displayed severe long-lasting motor asymmetry in the 
apomorphin-induced rotation test (Fig. 7C). Grafting 
firstly decreased the aggravation observed between 15 and 
45 days post-MCAO and, from 2 months, significantly 
reduced the deterioration. Baseline scores were compara-
ble in the three groups, indicating the absence of an initial 
unbalance in rotation scores: SA001: 42.5 ± 24.52; I-M5: 
33.6 ± 12.92; I-I90: 35.89 ± 13.18; one-way ANOVA: 
p = 0.36; F = 1.10; dll = 39. Other tests [Montoya staircase 
(Fig. 7B) and neurological scores] were not informative 
due to spontaneous resuming of pre-MCAO scores in 
nongrafted animals.
hiPSC-NPCs Project to Correct Target Areas
We used the hNCAM antibody to identify projec-
tions from grafted cells. One month after transplanta-
tion, hNCAM fibers were observed in myelinated fiber 
bundles of the host striatum and in the globus pallidus 
(Fig. 8A, B) at a maximal distance of 2 mm caudal to the 
injection site. No human fibers were observed in the host 
SN (Fig. 8C). After 2 months, human axons had extended 
throughout the entopedoncular nucleus (Fig. 8D, E) to the 
most caudal part of the SN (Fig. 8F–G). A dense graft-
derived axonal network was observed in SN pars reticu-
lata (SNr) (Fig. 8H), in close association to TH-positive 
dendrites (Fig. 8I). A few hNCAM fibers were observed 
in the thalamus and in the corpus callosum.
hiPS-NPCs Limit Secondary Neurodegeneration  
in the Host Brain
T2-weighted MRI in MCAO animals revealed a per-
sistent atrophy of the hindbrain at the level of the SN 
(Fig. 9A), which was confirmed at one month by TH 
staining (Fig. 9B). At 1 month, MCAO animals had a 
reduced SNr volume on the side ipsilateral to the lesion 
(61.1 ± 16.8% reduction compared to nonlesioned/non-
grafted animals; p = 0.010) (Fig. 9D). Figure 9C shows 
table 2. RT-PCR Quantification of mRNA Levels for hESC Genes in I-ShiPSC 
and SA001 hESC-Early Neural Progenitors (ENPs)
mRNA/Cell Line SA001-ENP I-M5-ENP I-I90-ENP
Oct-4 0.0067 ± 0.003 0.021 ± 0.001 0.01 ± 0.004
Nanog 0.0016 ± 0.02 0.196 ± 0.14* 0.134 ± 0.07*
Sox2 0.039 ± 0.006 0.108 ± 0.07* 0.076 ± 0.027
Mean ± SD of 2DDCt normalized to GAPDH. *p < 0.05 compared to SA001-ENPs.
Figure 4. Schematic time course of the experiments. Experiments start with the differentiation of pluripotent SCs into ENPs and 
banking. ENPs are thawed when MCAO is performed and are committed to NPCs for one week before transplantation. Animals 
were followed with magnetic resonance imaging (MRI) and behavioral analysis over 4 months, and histological data were acquired 
at 1, 2, and 4 months. Diff., differentiation; amplif., amplification; Behav., behavioral analysis; Histo., histological analysis; d, days 
post-MCAO.
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that variations among the three groups (SA001-NPCs, 
I-I90-NPCs, I-M5-NPCs) were not significant [one-way 
ANOVA: SN pars compacta (SNc): p = 0.66, F = 0.43, 
dll = 17; SNr p = 0.59, F = 0.54, dll = 17). Grafting 
reduced the atrophy of pars reticulata to 27.13 ± 11.50% 
(Fig. 9D) (p = 0.017, t = 2.26, dll = 8). MCAO-induced 
reduction of the volume occupied by TH cell bodies in 
pars compacta was not significant. However, nonbiased 
stereological quantification of TH-positive cell bodies 
(Fig. 9E)  indicated a 46.20 ± 12.41% loss of TH neu-
rons after MCAO (p = 0.03), reduced to a 21.11 ± 6.65% 
loss after grafting (p = 0.02) (Fig. 9F), corresponding to 
a 47% protection.
DISCuSSIOn
This study shows that intracerebral transplantation of 
hiPSC-NPCs in the subacute phase of cerebral ischemia 
has the potential to reverse functional deficits and to limit 
Figure 5. One month posttransplantation. (A) Animals with lesions restricted to the striatum were used in this study. (B) Animals 
with larger lesions were excluded. (C) The lesion (red arrow) and graft (white arrows) are distinguished on T2-weighed MRI by their 
intensity. (D) Postmortem histology shows the graft (arrow) in the lateral quadrant of the striatum. (E) Clusters of human (HNA) cells 
(arrows) have migrated away from injection site into the perilesional host parenchyma, although on short distances. Grafts contain a 
majority of nestin- (F), Sox2-, but no Oct4-positive cells (G), and small clusters of Pax6 cells (H). MAP2 processes originating from 
the graft gather into bundles to enter the host parenchyma (I, arrows). Grafts also contained TH-labeled fibers (J) and a small number of 
immature DARPP-32 neurons (L, M). (K) SA001-NPCgrafts had similar features, with clusters of immature DARPP-32 neurons (L).
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degeneration of remote brain structures connected to the 
lesion site.
On the cell biology aspect, this study firstly confirmed 
that hiPSC and hESC can respond to the same differentia-
tion protocol. NPCs were derived according to the dual-
SMAD inhibitor protocol developed for hESCs, based on 
the inhibition of nodal/activin and BMP signaling path-
ways and resulting in accelerated commitment of pluri-
potent SCs (PSCs) into NSCs (8). A main advantage of 
the NSC protocol is the rapid production of large pools 
of homogenous NPCs after 5–7 days of differentiation 
from frozen stocks. This protocol reduces individual dif-
ferences in neural commitment among PSCs (8).
Effective cell replacement therapy critically relies on 
the ability of transplanted progenitors to generate neurons 
with topographically relevant phenotypes. Striatal stroke 
induces massive loss of medium spiny GABAergic neu-
rons, leading to the disruption of the striatonigral loop. As 
described for hESC-NPCs in this model (6,42), grafted 
hiPSC-NPCs accurately generated long-projection GABA-
ergic neurons characterized by the D1 receptor second mes-
senger DARPP-32. The low percentage of DARPP-32 
Figure 6. Four months posttransplantation. (A) Cresyl violet staining showing the graft in the lateral striatum (black arrows). Grafts 
formed a mixed tissue with the host, with MTCO2-negative (B; arrow heads) endothelial cells and astrocytes (C). (D–F) Grafts con-
tained large clusters of DARPP-32 projection neurons (D, E), calretinin interneurons (F), and neurons with D2 dopaminergic recep-
tors (G). (H) Ki67 labeling showing dividing cells (arrow heads) of rat (MTCO2-negative) origin.
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neurons observed in grafts can be attributed to the lack 
of particular commitment during NPC differentiation and 
might be improved by specific differentiation protocols.
The second requirement for cell replacement therapy 
is accurate reconstruction of disrupted pathways (13). 
The ability of human neural progenitors to extend axons 
into the adult rat brain was first described by Wictorin 
and collaborators after excitotoxic striatal lesion (51). 
Subsequent studies have histologically (19) and elec-
trophysiologically (6,11,19) reported synaptic contacts 
between human NPCs and the adult rodent brain in stroke 
models. The possibility for human grafted neurons to 
form long-distance axonal projections is less documented 
and controversial. On one hand, few retrogradely labeled 
axons were observed in cortical transplants after injec-
tion of a tracer into the thalamus (16). Limited projection 
from grafted cortical tissue and the underlying striatum 
was reported in a model of cortical ischemia (44). On the 
other hand, Gaillard et al. observed specific connections 
between murine homotopic nigral transplants and the 
host striatum in a model of Parkinson’s disease (14) and 
from murine ESC-NPCs intracortical transplants to the 
host spinal cord (15). Reconstruction of the striatonigral 
loop was also achieved by simultaneous intrastriatal and 
intranigral grafting (31). A major result of our study was 
the fact that grafted hiPSC-NPCs extended axons toward 
Figure 7. Transplantation improves functional recovery. (A) Adhesive removal test for I-I90-NPCs-grafted animals show a complete 
recovery from the second week postgrafting (w, week; m, month). (B) Staircase test for I-M5-NPC-grafted animals show rapid spon-
taneous recovery in the nongrafted group; w, week postgrafting. ƒ, p < 0.05 compared to the pre-MCAO score in the corresponding 
group. (C) Apomorphin-induced rotation in nongrafted animals and animals grafted with NPC from I-M5, I-I90, and SA001. Scores 
are represented as percentage of MCAO baseline data. One-way ANOVA with Bonferroni–Dunn test for intergroups comparison at 
each experimental step. **p < 0.01, *p < 0.05.
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the remote host SN with great specificity. This suggests 
that hiPSC-NPCs have the potential to recognize their 
target over long distances in the adult postischemic brain. 
The molecular content of the dialogue that establishes 
between grafted cells and the recipient brain remains 
to be understood. It might relate to the particularly 
prone-to-remodeling state of the poststroke brain (32). 
Alternatively, axonal extension in a xenograft situation 
might result from an insensibility of human axons to the 
adult rat brain inhibitory molecules (41) that would nor-
mally prevent the growth of rat axons. Reciprocity of this 
dialogue was suggested by the rapid sprouting of host-
derived TH fibers into the grafts. The importance of host 
afferents in graft development has been emphasized in 
previous studies (12,29) and could have played a role in 
guiding the terminal differentiation of grafted neurons.
For cell replacement to be causally linked to res-
toration of impaired functions, a temporal relation-
ship should have existed between the maturation of 
graft-derived GABAergic neurons in the host stria-
tum and the kinetics of functional recovery. However, 
improvements of sensorimotor functions in the adhesive 
removal test occurred very rapidly and were temporally 
dissociated from both the maturation of GABAergic 
neurons in grafts and axonal projections to host target 
areas, which occurred weeks later. This temporal dis-
crepancy suggests the existence of mechanisms unre-
lated to the maturation and integration of grafted cells. 
Non cell-autonomous mechanisms have been evoked 
as major mediators of SCs effects in stroke, including 
with NPCs (5,26,35,36,38,43,53). They are commonly 
attributed to the release, by immature exogenous cells, 
Figure 8. I-ShiPS-NPCs project axons into the host brain. (A, B) After 1 month, human fibers were seen in the host globus pallidus 
(GP). CPu, caudate putamen nucleus. (C) No hNCAM-labeled fibers were seen in the SN. (D–I) Graft-derived axonal elongation at 
2 months. Axons are seen in the entopeduncular nucleus (D, E) and the SN (F, G) down to its caudalmost part (G). (H) Human axons 
intermingled with host TH-positive axons from the SN pars compacta at the entry of SN. (I) Graft-derived axons (green) in close appo-
sition to dopaminergic neuron dendrites (red) in pars reticulata.
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Figure 9. Transplantation prevents substantia nigra atrophy. (A) T2 weighted MRI shows a global atrophy of the right side (arrows) 
in a lesioned animal (MCAO) at 1 and 4 months post-MCAO, which is less conspicuous in grafted animals (MCAO+G; example of 
I-I90-NPCs graft). (B) Anti-TH immunohistochemistry in SN pars compacta (SNc) and pars reticulata (SNr) at 1 month. Delineation 
shows the area for volumetric measures. (C) Quantification of SNr and SNc volumes in animals grafted with the three lines-NPCs 
confirmed the homogeneity of the groups. (D) Grafting (MCAO+G) significantly reduce SNr atrophy induced by MCAO. *p < 0.05. 
(E) Illustration of the sampling for TH neuron counting. Insert shows the counting frame. Counts included neurons with visible nucleus 
present inside the frame or crossing the dashed line. (F) Quantification of TH-positive neurons in SNc, showing stroke-induced reduc-
tion and protection by grafting. One-way ANOVA with Bonferroni–Dunn test, *p < 0.05. NS, nonstatistically significant.
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of neuroprotective, antioxidant, and anti-inflammatory 
molecules that can both limit degeneration and improve 
the structural reorganization of the post-stroke brain. 
The characterization of this dialogue in our paradigm 
deserves further investigations.
In contrast with the rapid recovery of sensorimotor 
functions, improvements of motor ability in the apo-
morphin-induced test established slowly. Apomorphin is 
an agonist of dopaminergic receptors that requires matu-
ration of striatal neurons to be effective. The time course 
of motor recovery in this test nicely corresponded to the 
maturation of DARPP-32 neurons and to axonal projec-
tion to the SN.
Secondary alteration in areas functionally related to 
the lesion site after stroke has been described in patients 
(50) and animal models (33,46) and greatly contributes to 
long-term functional impairments. The reduction of TH 
fibers in the striatum directly correlates with the atrophy 
of the SN (22), and striatal administration of trophic fac-
tors after lesion of SN axons protects against SN degen-
eration. In addition, intrastriatal grafting of mesenchymal 
SCs reduced the sensitivity of SN neurons to the toxic-
ity of 6-hydroxydopamine (4,37), showing that SCs can 
exert a protective effect on SN neurons. We propose that 
the trophic effect exerted on host SN afferents by the graft 
was instrumental in promoting TH afferent sprouting into 
the graft and protecting the SN from atrophy, leading to 
rapid restoration of sensorimotor functions.
COnCluSIOnS
The driving force of current SC therapy research is to 
achieve a comprehensive understanding of the mecha-
nisms by which transplanted cells restore lost functions. 
So far, reported mechanisms include bystander effects 
nonrelated to intracerebral integration of exogenous cells 
and effects that directly rely on this integration. Due to 
its pathogenic characteristics, stroke can uniquely ben-
efit from this duality. In the acute phase, cell death and 
inflammation predominates and trophic, angiogenic, and/
or anti-inflammatory actions can reduce the severity of 
infarction without cell engraftment. In contrast, the post-
acute and chronic phases are times for intense axonal and 
synaptic reorganization that can be efficiently supported 
by integrated cells. As schematized in Figure 10, hiPSC-
NPCs might act both rapidly with unspecific trophic 
effects and, secondarily, through integration and recon-
struction of connections with host structures. A final step 
is needed before hiPSC-derived progenies enter the clinic, 
which relies on improvements of both the quality (to limit 
genetic and epigenetic modifications) and the availabil-
ity of cells. The production of “patient-tailored” hiPSC, 
which could avoid transplant rejection, is a months-taking 
procedure and might not fit with the emergency require-
ments of stroke treatment. In contrast, the iPSC strategy 
allows the derivation of HLA-compatible cell banks that 
might provide the ideal cell source for cell replacement 
therapy or more generally SC therapy in stroke.
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Figure 10. Suggested effects of hiPSC-NPCs grafted into the postischemic brain. Reciprocal connections link the substantia nigra (SN) to the 
striatum (STR). Stroke (MCAO) depletes the STR neuronal populations and deprives SN of both afferent and target cells, resulting in 
atrophy and partial cell death (no graft). Grafting (MCAO + Graft) firstly rescues the atrophy by providing SN striatal afferents with 
new targets and by promoting SN axonal sprouting (1. Trophic effect). Secondly, with maturation of transplanted cells, reconstruction 
of the STR-SN loop allows maintenance of functions (2. Reconstruction).
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